NEW YORK (GenomeWeb) — Cellgen Diagnostics said today that it has partnered with molecular testing firm Genomic Testing Cooperative (GTC) to offer companion diagnostic development services for cancer immunotherapy developers.
Under the terms of the deal, the companies will combine Cellgen's cartridge assay-based molecular diagnostics platform with GTC's biomarker discovery technologies to create a service for biomarker discovery and validation, as well as in vitro diagnostic companion assay development, for pharmaceutical industry customers.
According to Cellgen, its so-called Immune Panel assays enable patient stratification and therapeutic response monitoring, while GTC's technologies can be used to profile the tumor microenvironment to create patient phenotypic profiles.
The companies — both of which are based in Irvine, California — intend to first focus on next-generation sequencing applications in early-stage clinical programs. Additional terms were not disclosed.